| 24/04/23 | 07:00:09 | 24 Apr 2023 | | Bexmarilimab Efficacy and Safety in MATINS Trial | RNS |
| 19/04/23 | 07:00:06 | 19 Apr 2023 | | Bexmarilimab KOL Event | RNS |
| 18/04/23 | 07:00:07 | 18 Apr 2023 | | Poster Presentations at AACR 2023 | RNS |
| 17/04/23 | 07:00:05 | 17 Apr 2023 | | BEXMAB study update | RNS |
| 13/04/23 | 16:30:01 | 13 Apr 2023 | | Faron at Canaccord Oncology Virtual Conference | RNS |
| 29/03/23 | 07:00:05 | 29 Mar 2023 | | Appointment of Chief Financial Officer | RNS |
| 24/03/23 | 13:35:01 | 24 Mar 2023 | | Board Change | RNS |
| 24/03/23 | 13:30:01 | 24 Mar 2023 | | Results of AGM | RNS |
| 22/03/23 | 07:00:02 | 22 Mar 2023 | | Positive FDA Feedback to Progress Bexmarilimab | RNS |
| 03/03/23 | 09:00:01 | 3 Mar 2023 | | Notice of Faron Pharmaceuticals Ltd’s AGM | RNS |
| 03/03/23 | 07:15:01 | 3 Mar 2023 | | Faron´s Annual Report 2022 Published | RNS |
| 03/03/23 | 07:00:05 | 3 Mar 2023 | | Financial Statement January 1 to December 31 2022 | RNS |
| 06/02/23 | 18:00:01 | 6 Feb 2023 | | Update to Faron’s Financial Calendar for 2023 | RNS |
| 06/02/23 | 07:00:04 | 6 Feb 2023 | | Notice of 2022 Full-Year Results and Annual Report | RNS |
| 01/02/23 | 15:45:01 | 1 Feb 2023 | | Holding(s) in Company | RNS |
| 27/01/23 | 17:45:01 | 27 Jan 2023 | | Holding(s) in Company | RNS |
| 27/01/23 | 07:00:05 | 27 Jan 2023 | | Results of Placing | RNS |
| 26/01/23 | 16:30:00 | 26 Jan 2023 | | Proposed Issue and Placing | RNS |
| 16/01/23 | 11:00:14 | 16 Jan 2023 | | Price Monitoring Extension | RNS |
| 16/01/23 | 09:05:44 | 16 Jan 2023 | | Second Price Monitoring Extn | RNS |
| 16/01/23 | 09:00:21 | 16 Jan 2023 | | Price Monitoring Extension | RNS |
| 16/01/23 | 07:00:06 | 16 Jan 2023 | | Title: BEXMAB study update | RNS |
| 23/12/22 | 07:00:04 | 23 Dec 2022 | | Faron’s Financial Calendar for 2023 | RNS |
| 05/12/22 | 07:00:04 | 5 Dec 2022 | | BEXMAB Study Update | RNS |
| 01/12/22 | 07:00:03 | 1 Dec 2022 | | Faron Appoints Maija Hollmén PhD as CSO | RNS |
| 18/11/22 | 16:30:01 | 18 Nov 2022 | | Amendment Terms and Conditions with IPF Partners | RNS |
| 02/11/22 | 07:00:09 | 2 Nov 2022 | | Faron Announces Poster Presentation at SITC | RNS |
| 31/10/22 | 07:00:07 | 31 Oct 2022 | | BEXMAB Study Update | RNS |
| 19/10/22 | 09:20:01 | 19 Oct 2022 | | Holding(s) in Company | RNS |
| 18/10/22 | 12:30:06 | 18 Oct 2022 | | Holding(s) in Company | RNS |
| 18/10/22 | 07:00:06 | 18 Oct 2022 | | Faron Announces Melanoma Cohort Data from MATINS | RNS |
| 14/10/22 | 07:00:05 | 14 Oct 2022 | | Results of Placing | RNS |
| 13/10/22 | 17:31:01 | 13 Oct 2022 | | Proposed Issue and Placing of Shares | RNS |
| 22/09/22 | 07:00:14 | 22 Sept 2022 | | Grant of Options | RNS |
| 20/09/22 | 07:00:10 | 20 Sept 2022 | | Top-Line Data on Bexmarilimab Dose Variation | RNS |
| 14/09/22 | 07:00:13 | 14 Sept 2022 | | Faron to Host Bexmarilimab Update Webcast | RNS |
| 13/09/22 | 07:00:12 | 13 Sept 2022 | | Traumakine Data Presented at MHSR Symposium | RNS |
| 07/09/22 | 13:00:03 | 7 Sept 2022 | | Faron to Present at Upcoming Conferences | RNS |
| 25/08/22 | 07:00:03 | 25 Aug 2022 | | Faron Reports 2022 Half-Year Financial Results | RNS |
| 08/08/22 | 07:00:06 | 8 Aug 2022 | | Notice of Half-Year Financial Results | RNS |
| 07/07/22 | 09:45:04 | 7 Jul 2022 | | Results of EGM | RNS |
| 30/06/22 | 17:00:05 | 30 Jun 2022 | | Holding(s) in Company | RNS |
| 28/06/22 | 13:47:30 | 28 Jun 2022 | | Registration of New Shares | RNS |
| 28/06/22 | 07:00:08 | 28 Jun 2022 | | Announcement of Placing | RNS |
| 16/06/22 | 12:00:04 | 16 Jun 2022 | | Faron notice of EGM | RNS |
| 15/06/22 | 07:00:03 | 15 Jun 2022 | | Faron Announces Top-Line 12-Month Survival Results | RNS |
| 08/06/22 | 07:00:11 | 8 Jun 2022 | | First Patient Dosed in Ph I/II BEXMAB Combo Study | RNS |
| 01/06/22 | 07:00:08 | 1 Jun 2022 | | Exercise of options | RNS |
| 30/05/22 | 07:00:08 | 30 May 2022 | | Presentation of Biomarker Analysis at ASCO | RNS |
| 16/05/22 | 07:00:06 | 16 May 2022 | | FDA and FIMEA approve BEXMAB study to begin | RNS |
